INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 12, Issue 1- 2025

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.01.005

Hematological Complications in HIV-Infected Sickle Cell Patients: A Narrative Review

Emmanuel Ifeanyi Obeagu[1] and Olga Georgievna Goryacheva[2]
[1] Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, ORCID: 0000-0002-4538-0161
[2]Associate Professor, PhD, MD, Cadiologist, Internal Disease Doctor, Perm State Medical University Named after Academician E.A Wagner, Russia, ORCID: 0000-0002-3336-229X
*Corresponding Author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and Laboratory Science, Africa University, Zimbabwe, E-mail: emmanuelobeagu@yahoo.com, obeague@africau.edu, ORCID: 0000-0002-4538-0161

Abstract

Hematological complications in patients co-infected with Human Immunodeficiency Virus (HIV) and Sickle Cell Disease (SCD) present significant clinical challenges due to the complex interplay between these two conditions. Both HIV and SCD independently contribute to hematological abnormalities such as anemia, thrombocytopenia, and immune dysregulation, but their coexistence exacerbates these complications. Chronic hemolysis, bone marrow suppression, and immune system dysfunction in SCD patients are further aggravated by HIV-induced inflammation, opportunistic infections, and the hematotoxic effects of certain antiretroviral therapies (ART). This overlapping pathology complicates disease management and increases the risk of morbidity and mortality in affected individuals. Anemia is the most common hematological complication in HIV-infected SCD patients, resulting from a combination of chronic hemolysis, impaired erythropoiesis, and nutritional deficiencies. Thrombocytopenia, driven by autoimmune destruction and splenic sequestration, increases the risk of bleeding, particularly during vaso-occlusive crises. Additionally, immune dysfunction caused by HIV further compromises leukocyte function, heightening susceptibility to severe infections. The hypercoagulable state induced by both diseases increases the risk of thrombotic events, complicating therapeutic strategies that require careful balancing between anticoagulation and bleeding prevention.

Keywords: Sickle Cell Disease, HIV, Hematological Complications, Anemia, Thrombocytopenia

Introduction

Sickle Cell Disease (SCD) and Human Immunodeficiency Virus (HIV) are two significant global health challenges, particularly prevalent in sub-Saharan Africa where the burden of both diseases often overlaps. SCD is an inherited hemoglobinopathy characterized by chronic hemolysis, vaso-occlusive crises (VOC), and progressive organ damage due to the sickling of red blood cells. HIV, on the other hand, is a viral infection that causes immune suppression by targeting CD4+ T lymphocytes, leading to acquired immunodeficiency syndrome (AIDS) if untreated. Individually, these conditions are associated with significant morbidity and mortality, but their co-occurrence introduces a complex clinical scenario that exacerbates hematological complications and complicates disease management.[1-5] The prevalence of HIV in individuals with SCD is a growing concern due to increased survival rates among SCD patients and the widespread nature of HIV in endemic regions. While some early studies suggested that SCD patients might have a lower risk of acquiring HIV due to increased hemolysis and elevated hemoglobin F levels, recent evidence has shown that these individuals are just as susceptible to HIV infection as the general population. This co-infection creates a compounded health burden, as both conditions independently and synergistically impair hematopoiesis, immune function, and overall physiological stability.[6-10] Hematological complications are central to the clinical manifestations of both HIV and SCD. In SCD, chronic anemia arises from continuous hemolysis and ineffective erythropoiesis, while HIV contributes to anemia through bone marrow suppression, chronic inflammation, and opportunistic infections. Additionally, antiretroviral therapy (ART), although essential for managing HIV, can induce myelotoxicity, further aggravating anemia. The compounded effect of both diseases leads to more severe and persistent anemia, negatively impacting the patient's quality of life and increasing the risk of life-threatening complications.[11-12]

Thrombocytopenia, characterized by a reduced platelet count, is another significant hematological complication in HIV-infected SCD patients. In SCD, splenic sequestration and chronic platelet activation contribute to platelet abnormalities, while HIV induces immune-mediated platelet destruction. This dual mechanism heightens the risk of bleeding episodes, especially during VOC or surgical interventions. Furthermore, ART regimens, particularly those containing zidovudine, can suppress platelet production, worsening thrombocytopenia and complicating clinical management.[13-14] Immune dysregulation is a hallmark of HIV infection, leading to progressive immunosuppression. In SCD, the immune system is already compromised due to functional asplenia, chronic inflammation, and frequent infections. The combination of HIV and SCD results in profound immune dysfunction, increasing susceptibility to opportunistic infections and impairing the body's ability to respond to vaccinations. This immunocompromised state demands vigilant infection control measures and tailored immunization strategies to mitigate infection-related morbidity and mortality.[15-16] Coagulation abnormalities are also more pronounced in HIV-infected SCD patients. Both conditions promote a hypercoagulable state due to endothelial dysfunction, increased tissue factor expression, and chronic inflammation. This prothrombotic environment elevates the risk of venous thromboembolism, stroke, and other vascular complications. Managing these coagulation disorders is particularly challenging because anticoagulant therapy must be carefully balanced against the heightened risk of bleeding due to thrombocytopenia and fragile blood vessels.[17-19] The management of hematological complications in HIV-infected SCD patients is further complicated by the potential hematotoxicity of ART. Drugs such as zidovudine can cause bone marrow suppression, leading to pancytopenia. Clinicians must carefully select ART regimens that minimize hematological side effects while effectively suppressing HIV replication. Regular monitoring of hematological parameters and early intervention for cytopenias are critical components of comprehensive care in this population.[20-21]

Hematological Abnormalities in HIV-Infected Sickle Cell Patients

Co-infection with Human Immunodeficiency Virus (HIV) and Sickle Cell Disease (SCD) leads to a complex spectrum of hematological abnormalities, significantly complicating clinical management. Both conditions independently cause profound changes in blood components, but their coexistence amplifies the severity of hematological complications. Key abnormalities observed in HIV-infected SCD patients include anemia, thrombocytopenia, leukopenia, coagulation disorders, and bone marrow dysfunction.[22-23]

1. Anemia

Anemia is a common and severe complication in patients co-infected with HIV and SCD. In SCD, chronic hemolysis and impaired erythropoiesis due to bone marrow stress result in persistent anemia. Additionally, HIV exacerbates anemia through multiple mechanisms, including chronic inflammation, bone marrow suppression, opportunistic infections, and nutritional deficiencies. Certain antiretroviral therapies (ART), especially zidovudine, can also induce bone marrow suppression, worsening anemia. This combined burden often leads to more severe and treatment-resistant anemia, contributing to fatigue, reduced exercise tolerance, and increased hospitalization rates. Management requires addressing the underlying causes, optimizing ART regimens, supplementing with iron or folate when necessary, and considering erythropoiesis-stimulating agents.[24-25]

2. Thrombocytopenia

Thrombocytopenia, or low platelet count, is frequently observed in HIV-infected SCD patients. In SCD, splenic sequestration and chronic platelet activation contribute to platelet consumption, while HIV induces immune-mediated platelet destruction and decreases platelet production. This dual mechanism increases the risk of spontaneous bleeding and complicates surgical procedures or vaso-occlusive crises. Certain ART drugs may further impair platelet production, intensifying the problem. Treatment strategies include managing HIV replication with effective ART, using corticosteroids or intravenous immunoglobulin for immune thrombocytopenia, and closely monitoring platelet counts to prevent bleeding complications.[26-27]

3. Leukopenia and Immune Dysregulation

Leukopenia, particularly neutropenia and lymphopenia, is another critical hematological abnormality in co-infected patients. HIV progressively destroys CD4+ T cells and impairs neutrophil and monocyte function, while SCD contributes to chronic inflammation and immune dysregulation. Functional asplenia in SCD further weakens immune defenses, increasing vulnerability to infections. This compromised immune system heightens the risk of bacterial, fungal, and viral infections, particularly during episodes of vaso-occlusion. Preventive strategies include prophylactic antibiotics, routine vaccinations, and regular monitoring of white blood cell counts to enable early detection and treatment of infections.[28-29]

4. Coagulation Abnormalities

Both HIV and SCD promote a hypercoagulable state, increasing the risk of thrombotic events. In SCD, chronic endothelial activation, increased tissue factor expression, and elevated levels of procoagulant factors contribute to thrombosis. HIV infection adds to this risk through chronic immune activation, endothelial dysfunction, and dysregulated coagulation pathways. Consequently, co-infected patients are more susceptible to deep vein thrombosis (DVT), pulmonary embolism, and stroke. Balancing anticoagulation therapy to prevent clot formation while minimizing bleeding risks from thrombocytopenia remains a significant clinical challenge. Individualized risk assessment and close monitoring are essential for safe and effective management.[30-31]

5. Bone Marrow Dysfunction

Bone marrow dysfunction is exacerbated in HIV-infected SCD patients due to the combined effects of chronic marrow hyperactivity and HIV-related suppression. SCD drives bone marrow hyperplasia in response to chronic hemolysis, while HIV infection and certain ART regimens (e.g., zidovudine) suppress hematopoiesis, leading to pancytopenia. This can result in severe anemia, leukopenia, and thrombocytopenia, further complicating disease management. Careful selection of ART with minimal myelotoxicity, along with regular blood count monitoring, is critical in mitigating bone marrow suppression and maintaining hematopoietic function.[32-33]

6. Hemolysis and Red Blood Cell (RBC) Destruction

SCD is inherently characterized by chronic hemolysis due to the sickling and subsequent destruction of red blood cells. HIV infection can intensify hemolysis through immune-mediated mechanisms, increased oxidative stress, and opportunistic infections. Additionally, ART-induced hypersensitivity reactions and drug-induced hemolytic anemia can occur. This heightened hemolytic activity leads to worsening anemia, increased bilirubin levels, and a higher risk of gallstones and leg ulcers. Management focuses on controlling SCD-related hemolysis, selecting ART regimens with a lower risk of hemolytic side effects, and providing supportive care to manage anemia-related symptoms.[34-35]

7. Iron Overload

Iron overload is a potential complication in HIV-infected SCD patients, primarily due to repeated blood transfusions used to manage severe anemia and prevent stroke. Excess iron accumulation can lead to organ damage, including liver fibrosis, heart dysfunction, and endocrine disorders. Additionally, HIV-related inflammation may disrupt iron metabolism, contributing to dysregulated iron storage. Regular monitoring of serum ferritin levels and iron studies, along with the use of iron chelation therapy when necessary, is essential to prevent iron-induced organ toxicity.[36]

8. Macrocytosis

Macrocytosis, characterized by enlarged red blood cells, is a frequently observed hematological abnormality in HIV-infected SCD patients, often resulting from ART, particularly zidovudine. In SCD, increased erythropoietic activity can also contribute to macrocytosis. Although generally asymptomatic, macrocytosis may signal underlying bone marrow stress or folate deficiency. Monitoring mean corpuscular volume (MCV) levels and addressing nutritional deficiencies or ART-related toxicity is important for comprehensive hematological management.[36]

Impact of Antiretroviral Therapy (ART) on Hematological Outcomes

Antiretroviral therapy (ART) has revolutionized the management of HIV infection, significantly improving survival rates and quality of life for individuals living with the virus. However, in HIV-infected Sickle Cell Disease (SCD) patients, the impact of ART on hematological outcomes is complex and multifaceted. While ART effectively suppresses viral replication and restores immune function, it can also contribute to various hematological complications due to drug-induced toxicity and interactions with the underlying pathology of SCD.[37]

1. ART-Induced Anemia

One of the most significant hematological complications associated with ART in HIV-infected SCD patients is anemia. Certain antiretroviral drugs, particularly nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine (AZT), are known to cause bone marrow suppression, impairing erythropoiesis. In patients with SCD, who already suffer from chronic hemolytic anemia, the additional marrow suppression from ART can exacerbate anemia, leading to severe fatigue, increased transfusion dependence, and a higher risk of organ dysfunction. The use of zidovudine has

declined in favor of less hematotoxic drugs, but anemia remains a critical concern in ART management for SCD patients. Careful selection of ART regimens that minimize hematological toxicity is essential to reduce anemia-related complications.[38]

2. Thrombocytopenia and Platelet Dysfunction

Thrombocytopenia is a common hematological abnormality in HIV-infected individuals, often resulting from immune-mediated platelet destruction, direct HIV infection of megakaryocytes, and ART toxicity. In SCD patients, splenic sequestration and platelet activation already contribute to low platelet counts. ART drugs like zidovudine and some protease inhibitors (PIs) can further impair platelet production, worsening thrombocytopenia and increasing the risk of bleeding. Moreover, ART-induced platelet dysfunction can impair clot formation, complicating the management of vaso-occlusive crises and surgical procedures. Close monitoring of platelet counts and the use of ART regimens with lower hematologic toxicity are crucial for mitigating bleeding risks in co-infected patients.[39]

3. Neutropenia and Immune Suppression

Neutropenia, or low neutrophil count, is another hematological side effect of ART that can be particularly problematic for HIV-infected SCD patients. Drugs such as zidovudine and ganciclovir can suppress neutrophil production, increasing the risk of bacterial and fungal infections. In SCD, functional asplenia and chronic inflammation already weaken immune defenses. The compounded effect of ART-induced neutropenia and immune dysregulation can lead to frequent and severe infections, prolonged hospitalizations, and increased mortality. Regular monitoring of white blood cell counts and the use of growth factors like granulocyte colony-stimulating factor (G-CSF) in severe cases may help manage neutropenia and reduce infection-related complications.[40]

4. Macrocytosis

Macrocytosis, characterized by enlarged red blood cells, is a common hematological finding in patients receiving ART, especially those on zidovudine. This drug impairs DNA synthesis in erythroid precursors, leading to macrocytosis. Although typically asymptomatic, macrocytosis may signal underlying bone marrow stress or nutritional deficiencies (e.g., folate or vitamin B12). In SCD patients, who already have increased erythropoietic activity, macrocytosis can be more pronounced and may mask or worsen anemia. Monitoring mean corpuscular volume (MCV) and addressing any underlying deficiencies are essential to managing this condition effectively.[41]

5. Bone Marrow Suppression

Bone marrow suppression is a well-documented side effect of certain ART drugs, particularly zidovudine and stavudine. These drugs interfere with mitochondrial DNA replication in hematopoietic stem cells, leading to pancytopenia—anemia, leukopenia, and thrombocytopenia. In SCD patients, chronic marrow hyperplasia due to compensatory erythropoiesis makes the bone marrow more vulnerable to suppression. This can result in severe cytopenias, increasing the risk of infections, bleeding, and organ damage. Selecting ART regimens with a lower risk of bone marrow toxicity and implementing routine blood monitoring are essential strategies for preventing severe marrow suppression.[42]

6. Improved Hematological Outcomes with Modern ART Regimens

The introduction of newer ART regimens with improved safety profiles has significantly reduced the incidence of hematological complications. Drugs such as tenofovir, lamivudine, and integrase strand transfer inhibitors (INSTIs) like dolutegravir have minimal hematologic toxicity compared to older drugs like zidovudine. These modern regimens offer effective viral suppression with fewer side effects, leading to improved hematological outcomes and better overall health in HIV-infected SCD patients. Personalized ART

regimens that account for pre-existing hematological abnormalities are critical for optimizing patient outcomes.[43]

7. Impact on Inflammation and Vaso-Occlusive Crises

Effective ART reduces HIV-associated chronic inflammation, which may indirectly benefit SCD patients by lowering the frequency and severity of vaso-occlusive crises (VOC). Chronic inflammation contributes to endothelial dysfunction and coagulation abnormalities in both HIV and SCD. By suppressing viral replication and decreasing systemic inflammation, ART can improve vascular health and reduce hypercoagulability, potentially lowering the risk of thrombosis and VOC. However, this benefit must be balanced against the hematological side effects of certain ART drugs that can exacerbate anemia or thrombocytopenia.[44]

8. Balancing ART Efficacy with Hematological Safety

Managing HIV in SCD patients requires a careful balance between effective viral suppression and minimizing hematological toxicity. ART regimens should be tailored to avoid drugs with high myelotoxicity while maintaining potent antiviral activity. Regular hematological monitoring is essential to detect and manage anemia, neutropenia, and thrombocytopenia early. Supportive care, including nutritional supplementation, blood transfusions when necessary, and growth factors, can mitigate ART-related hematological complications. Collaborative care involving hematologists and infectious disease specialists is crucial to optimizing treatment strategies and improving patient outcomes.[45]

Conclusion

The coexistence of HIV infection and Sickle Cell Disease (SCD) presents a complex clinical challenge due to the compounded hematological abnormalities arising from both conditions. HIV exacerbates pre-existing hematological complications in SCD patients, leading to more severe anemia, thrombocytopenia, leukopenia, coagulation abnormalities, and bone marrow dysfunction. Antiretroviral therapy (ART), while essential for controlling HIV replication and improving immune function, can also contribute to hematological toxicity, further complicating disease management. Drugs like zidovudine have been associated with bone marrow suppression, worsening anemia and cytopenias in this vulnerable population. However, the advent of newer ART regimens with improved safety profiles has offered significant progress in minimizing these hematological risks. Optimizing the management of HIV-infected SCD patients requires a multidisciplinary approach that carefully balances effective viral suppression with the prevention and treatment of hematological complications. This involves selecting ART regimens with minimal myelotoxicity, closely monitoring blood counts, providing supportive therapies such as transfusions and growth factors, and implementing preventive measures against infections. Collaborative care between hematologists and infectious disease specialists is essential for personalized treatment plans that address both the infectious and hematological dimensions of care.

References

1. Owusu ED, Visser BJ, Nagel IM, Mens PF, Grobusch MP. The interaction between sickle cell disease and HIV infection: a systematic review. Clinical Infectious Diseases. 2015; 60(4):612-626.
2. Boateng LA, Ngoma AM, Bates I, Schonewille H. Red blood cell alloimmunization in transfused patients with sickle cell disease in sub-Saharan Africa; a systematic review and meta-analysis. Transfusion Medicine Reviews. 2019; 33(3):162-169.
3. Ola B, Olushola O, Ebenso B, Berghs M. Sickle Cell Disease and Its Psychosocial Burdens in Africa. InSickle Cell Disease in Sub-Saharan Africa 2024: 67-80. Routledge.
4. Makani J, Ofori-Acquah SF, Nnodu O, Wonkam A, Ohene-Frempong K. Sickle cell disease: new opportunities and challenges in Africa. The scientific world journal. 2013; 2013(1):193252.

5. Ochocinski D, Dalal M, Black LV, Carr S, Lew J, Sullivan K, Kissoon N. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Frontiers in Pediatrics. 2020; 8:38.
6. Obeagu EI, Obeagu GU, Okwuanaso CB. Optimizing Immune Health in HIV Patients through Nutrition: A Review. Elite Journal of Immunology, 2024; 2(1): 14-33
7. Obeagu EI, Obeagu GU. Platelet Distribution Width (PDW) as a Prognostic Marker for Anemia Severity in HIV Patients: A Comprehensive Review. Journal home page: http://www. journalijiar. com.;12(01).
8. Obeagu EI, Ubosi NI, Obeagu GU, Akram M. Early Infant Diagnosis: Key to Breaking the Chain of HIV Transmission. Elite Journal of Public Health, 2024; 2 (1): 52-61
9. Obeagu EI, Obeagu GU. Hematocrit Fluctuations in HIV Patients Co-infected with Malaria Parasites: A Comprehensive Review. Int. J. Curr. Res. Med. Sci. 2024; 10(1):25-36.
10. Obeagu EI, Obeagu GU. Transfusion Therapy in HIV: Risk Mitigation and Benefits for Improved Patient Outcomes. Asian J Dental Health Sci, 2024; 4(1):32-7. Available from: http://ajdhs.com/index.php/journal/article/view/62
11. Obeagu EI, Obeagu GU. Advancements in HIV Prevention: Africa's Trailblazing Initiatives and Breakthroughs. Elite Journal of Public Health, 2024; 2 (1): 52-63
12. Obeagu EI, Obeagu GU. Optimizing Blood Transfusion Protocols for Breast Cancer Patients Living with HIV: A Comprehensive Review. Elite Journal of Nursing and Health Science, 2024; 2(2):1-17
13. Obeagu EI, Obeagu GU. Understanding ART and Platelet Functionality: Implications for HIV Patients. Elite Journal of HIV, 2024; 2(2): 60-73 1
14. Obeagu EI, Obeagu GU. Hematologic Considerations in Breast Cancer Patients with HIV: Insights into Blood Transfusion Strategies. Elite Journal of Health Science, 2024; 2(2): 20-35
15. Obeagu EI, Obeagu GU. Impact of Maternal Eosinophils on Neonatal Immunity in HIV Exposed Infants: A Review. Elite Journal of Immunology, 2024; 2(3): 1-18
16. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. Newport International Journal of Biological and Applied Sciences (NIJBAS) 2023. http://hdl.handle.net/20.500.12493/14626
17. Ntsekhe M, Baker JV. Cardiovascular disease among persons living with HIV: new insights into pathogenesis and clinical manifestations in a global context. Circulation. 2023; 147(1):83-100.
18. Obare LM, Temu T, Mallal SA, Wanjalla CN. Inflammation in HIV and its impact on atherosclerotic cardiovascular disease. Circulation research. 2024; 134(11):1515-1545
19. Hmiel L, Zhang S, Obare LM, Santana MA, Wanjalla CN, Titanji BK, Hileman CO, Bagchi S. Inflammatory and immune mechanisms for atherosclerotic cardiovascular disease in HIV. International journal of molecular sciences. 2024; 25(13):7266..
20. Obeagu EI, Obeagu GU. Platelet Aberrations in HIV Patients: Assessing Impacts of ART. Elite Journal of Haematology, 2024; 2(3): 10-24
21. Obeagu EI, Obeagu GU. Harnessing B Cell Responses for Personalized Approaches in HIV Management. Elite Journal of Immunology, 2024; 2(2): 15-28
22. Belisário AR, Blatyta PF, Vivanco D, Oliveira CD, Carneiro-Proietti AB, Sabino EC, de Almeida-Neto C, Loureiro P, Máximo C, de Oliveira Garcia Mateos S, Flor-Park MV. Association of HIV infection with clinical and laboratory characteristics of sickle cell disease. BMC Infectious Diseases. 2020; 20(1):638.
23. Bhowmik A, Banerjee P. Hematological manifestation in HIV infected children. J Coll Physicians Surg Pak. 2015; 25(2):119-123.
24. Gill AF, Ahsan MH, Lackner AA, Veazey RS. Hematologic abnormalities associated with simian immunodeficieny virus (SIV) infection mimic those in HIV infection. Journal of Medical Primatology. 2012; 41(3):214-224.

25. Nouraie M, Nekhai S, Gordeuk VR. Sickle cell disease is associated with decreased HIV but higher HBV and HCV comorbidities in US hospital discharge records: a cross-sectional study. Sexually transmitted infections. 2012; 88(7):528-533.
26. Obeagu EI, Obeagu GU. Hematological Changes Following Blood Transfusion in Young Children with Severe Malaria and HIV: A Critical Review. Elite Journal of Laboratory Medicine. 2024; 2(1):33-45.
27. Obeagu EI, Obeagu GU. The Role of L-selectin in Tuberculosis and HIV Coinfection: Implications for Disease Diagnosis and Management. Elite Journal of Public Health, 2024; 2 (1): 35-51
28. Obeagu EI, Obeagu GU. Unraveling the Role of Eosinophil Extracellular Traps (EETs) in HIV-Infected Pregnant Women: A Review. Elite Journal of Nursing and Health Science, 2024; 2(3): 84-99
29. Obeagu EI, Obeagu GU. Unveiling the Role of Innate Immune Activation in Pediatric HIV: A Review. Elite Journal of Immunology, 2024; 2(3): 33-44
30. Obeagu EI, Obeagu, GU. Impact of Blood Transfusion on Viral Load Dynamics in HIVPositive Neonates with Severe Malaria: A Review. Elite Journal of Scientific Research and Review, 2024; 2(1): 42-60
31. Obeagu EI, Obeagu GU. L-selectin and HIV-Induced Immune Cell Trafficking: Implications for Pathogenesis and Therapeutic Strategies . Elite Journal of Laboratory Medicine, 2024; 2(2): 30-46
32. Obeagu EI, Obeagu GU. Exploring the Role of L-selectin in HIV-related Immune Exhaustion: Insights and Therapeutic Implications. Elite Journal of HIV, 2024; 2(2): 43-59
33. Obeagu EI, Obeagu GU. P-Selectin Expression in HIV-Associated Coagulopathy: Implications for Treatment. Elite Journal of Haematology, 2024; 2(3): 25-41
34. Obeagu EI, Obeagu GU. P-Selectin and Immune Activation in HIV: Clinical Implications. Elite Journal of Health Science, 2024; 2(2): 16-29
35. Obeagu EI, Amaeze AA, Ogbu ISI, Obeagu GU. B Cell Deficiency and Implications in HIV Pathogenesis: Unraveling the Complex Interplay. Elite Journal of Nursing and Health Science, 2024; 2(2): 33-46
36. Obeagu EI, Obeagu, GU. Platelet Dysfunction in HIV Patients: Assessing ART Risks. Elite Journal of Scientific Research and Review, 2024; 2(1): 1-16
37. Kibaru EG, Nduati R, Wamalwa D, Kariuki N. Impact of highly active antiretroviral therapy on hematological indices among HIV-1 infected children at Kenyatta National Hospital-Kenya: retrospective study. AIDS research and therapy. 2015; 12:1-8.
38. Enawgaw B, Alem M, Addis Z, Melku M. Determination of hematological and immunological parameters among HIV positive patients taking highly active antiretroviral treatment and treatment naïve in the antiretroviral therapy clinic of Gondar University Hospital, Gondar, Northwest Ethiopia: a comparative cross-sectional study. BMC hematology. 2014; 14:1-7.
39. Gudina A, Wordofa M, Urgessa F. Immuno-hematological parameters among adult HIV patients before and after initiation of Dolutegravir based antiretroviral therapy, Addis Ababa, Ethiopia. Plos one. 2024; 19(10):e0310239.
40. Geletaw T, Tadesse MZ, Demisse AG. Hematologic abnormalities and associated factors among HIV infected children pre-and post-antiretroviral treatment, North West Ethiopia. Journal of blood medicine. 2017:99-105.
41. Jegede FE, Oyeyi TI, Abdulrahman SA, Mbah HA, Badru T, Agbakwuru C, Adedokun O. Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria. PLoS One. 2017; 12(3):e0174233.
42. Obeagu EI, Obeagu GU. ART and Platelet Dynamics: Assessing Implications for HIV Patient Care. Elite Journal of Haematology. 2024; 2(4):68-85.
43. Obeagu EI, Ayogu EE, Obeagu GU. Impact on Viral Load Dynamics: Understanding the Interplay between Blood Transfusion and

Antiretroviral Therapy in HIV Management. Elite Journal of Nursing and Health Science. 2024;2(2):5-15.
44. Ciccacci F, Lucaroni F, Latagliata R, Morciano L, Mondlane E, Balama M, Tembo D, Gondwe J, Orlando S, Palombi L, Marazzi MC. Hematologic alterations and early mortality in a cohort of HIV positive African patients. PLoS One. 2020; 15(11):e0242068.
45. Ashenafi G, Tibebu M, Tilahun D, Tsegaye A. Immunohematological Outcome Among Adult HIV Patients Taking Highly Active Antiretroviral Therapy for at Least Six Months in Yabelo Hospital, Borana, Ethiopia. Journal of Blood Medicine. 2023:543-554.

Access this Article in Online

Website: www.ijcrcps.com

Subject: Haematology

Quick Response Code

DOI: 10.22192/ijcrcps.2025.12.01.05

How to cite this article:
Emmanuel Ifeanyi Obeagu and Olga Georgievna Goryacheva. (2025). Hematological Complications in HIV-Infected Sickle Cell Patients: A Narrative Review. Int. J. Curr. Res. Chem. Pharm. Sci. 12(1): 44-52.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.01.005

